Document Detail

The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of NHLBI Type II Coronary Intervention Study.
MedLine Citation:
PMID:  6360415     Owner:  NLM     Status:  MEDLINE    
The National Heart, Lung and Blood Institute Type II Coronary Intervention Study, a double-blind, placebo-controlled trial, evaluated the efficacy of reduction in cholesterol levels induced by cholestyramine on progression of coronary artery disease (CAD). The rate of CAD progression in patients treated with cholestyramine plus diet was compared with that of patients treated with placebo plus diet. CAD progression was defined angiographically. Significant decrease in total cholesterol (TC) and low-density lipoprotein cholesterol (LDLc) and increases in high-density lipoprotein cholesterol (HDLc), as well as in HDLc/TC and HDLc/LDLc ratios, were observed with cholestyramine. HDLc change was due to increase in HDL2A and HDL2B. When the relationship between CAD progression and lipid changes was examined independent of specific treatment group, a significant inverse relationship was found between progression at 5 years and the combination of an increase in HDLc and a decrease in LDLc; changes in HDLc/TC and HDLc/LDLc were the best predictors of CAD change. While the testing of these relationships independent of treatment group was not part of the initial study design, the trends were observed in both the placebo-treated and cholestyramine-treated groups. Moreover, with multivariate analysis, the effect of cholestyramine treatment on CAD progression was eliminated by adding changes in HDLc/TC to the regression model. These findings support the hypothesis that increases in HDLc and decreases in TC (or LDLc) can prevent or delay CAD progression.
R I Levy; J F Brensike; S E Epstein; S F Kelsey; E R Passamani; J M Richardson; I K Loh; N J Stone; R F Aldrich; J W Battaglini
Related Documents :
1520045 - Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein ...
19932775 - Effects of combination lipid therapy on coronary stenosis progression and clinical card...
15461565 - Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester trans...
9785055 - Detection and evaluation of dyslipoproteinemia.
17821855 - Chronic maternal dietary iodine deficiency but not thiocyanate feeding affects maternal...
25392345 - The efficacy of antioxidant therapy against oxidative stress and androgen rise in ethyl...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Circulation     Volume:  69     ISSN:  0009-7322     ISO Abbreviation:  Circulation     Publication Date:  1984 Feb 
Date Detail:
Created Date:  1984-02-22     Completed Date:  1984-02-22     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  325-37     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholesterol / blood
Cholesterol, HDL
Cholesterol, LDL
Cholestyramine Resin / therapeutic use*
Clinical Trials as Topic
Coronary Disease / blood,  complications,  diagnosis*
Double-Blind Method
Hypercholesterolemia / blood,  complications,  diet therapy,  drug therapy*
Lipoproteins, HDL / blood
Lipoproteins, LDL / blood
Middle Aged
Triglycerides / blood
Grant Support
Reg. No./Substance:
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Triglycerides; 11041-12-6/Cholestyramine Resin; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the N...
Next Document:  A fluorescent immunoassay for theophylline: description and comparison to enzyme immunoassay, liquid...